This article is translated from press release in Japanese for your convenience. Forward-Looking Statements Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management... Read more
Q3 2022 reported revenue growth of 4.9% year-over-year (yoy); organic revenue growth of 12.7% Q3 2022 GAAP operating margin 20.6%; non-GAAP operating margin 22.4%, up 180 basis points yoy Q3 2022 GAAP EPS $0.59; non-GAAP EPS $0.66, up 4.8% yoy Given strong year-to-date performance and high backlog, Bruker is raising its FY 2022 guidance for... Read more
Announces $1.0 Billion Share Repurchase Program for Q4 2022 Separately Enters Into Agreement to Acquire The Binding Site Group WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today provided an update on capital deployment. Throughout the fourth quarter of 2022, Thermo Fisher expects to execute a... Read more
Expands Specialty Diagnostics Segment with Industry Leader in Oncology Testing for Detection and Monitoring of Multiple Myeloma Complements Existing Specialty Diagnostics Offering with Established Technologies Delivering Strong Clinical Value for Patients in a Rapidly Growing Diagnostics Segment WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today... Read more
WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended October 1, 2022. Third Quarter 2022 Highlights Third quarter revenue was $10.68 billion. Third quarter GAAP diluted earnings per share (EPS) was $3.79. Third quarter adjusted EPS was $5.08. Delivered... Read more
Collaboration places emphasis on personalized medicine; brings together key precision diagnostic and treatment delivery tools aimed at creating shorter, more comfortable and more effective treatments for patients CHICAGO, IL and SUNNYVALE, Calif., – October 21, 2022: GE Healthcare and Accuray Incorporated (NASDAQ: ARAY) announced today that they have signed a global commercial collaboration agreement designed... Read more
Of the more than 500 devices included by the U.S. FDA on a recently updated list of AI-enabled device authorizations, 42 are from GE Healthcare, a milestone that highlights the impact of the company’s digital strategy. Chicago – October 20, 2022 – On a recently updated FDA list of artificial intelligence (AI) enabled medical devices,... Read more
WASHINGTON, Oct. 20, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the third quarter 2022. All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended September 30, 2022, net earnings were $1.6 billion, or $2.10 per diluted common share which represents a 36.0% year-over-year... Read more
A partnership to foster Enterprise imaging and pathology for oncology The collaboration intends to bring a data management solution by interfacing Tribun’s Health Suite data into GE Healthcare’s products Buc, France – October 18, 2022 – GE Healthcare and Tribun Health have entered a collaboration with the intent to provide digital pathology departmental solutions that... Read more
Extending deep learning-based AIR Recon DL compatibility to 3D & PROPELLER has the potential to enable more confident patient diagnoses in MRI Chicago, US, September 29, 2022 – GE Healthcare announced US FDA 510(k) clearance of its breakthrough AIR Recon DL for 3D and PROPELLER imaging sequences[1]. The benefits of AIR Recon DL are extended... Read more